Neurogene Inc. Debt Securities, Available-for-sale, Unrealized Gain
Neurogene Inc. (NGNE) reported Debt Securities, Available-for-sale, Unrealized Gain of $10.00 thousand for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-12.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2015-05-12
- Neurogene Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2015-03-31 was $10.00K.
- Neurogene Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2014-12-31 was $13.50K.
- Neurogene Inc. debt securities, available-for-sale, unrealized gain for fiscal 2014 was $20.80K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2015-03-31 | $10.00K 10-Q · filed 2015-05-12 | $23.50K derived: sum of 2 quarters · filed 2015-05-12 | ||
| 2014-12-31 | $13.50K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $20.80K 10-K · filed 2015-03-16 | ||
| 2014-09-30 | $7.30K 10-Q · filed 2014-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |